June 13, 2000

DRAFT AGENDA BLOOD PRODUCTS ADVISORY COMMITTEE 66th Meeting - June 15-16, 2000 Holiday Inn, Silver Spring 8777 Georgia Avenue, Silver Spring, MD

Thursday, June 15, 2000

8:00 a.m. Statement of Conflict of Interest8:05 a.m. Welcome and Opening Remarks8:10 a.m. Committee Updates

- Summary of PHS Advisory Committee on Blood Safety and Availability Meeting, April 25-26, 2000, Stephen Nightingale, M.D.
- Summary of Workshop on Plasticizers: Scientific Issues in Blood Collection, Storage, and Transfusion, October 18, 1999 -Jaroslav Vostal, M.D., Ph.D.
- Report on Blood Supply Monitoring Paul McCurdy, M.D.
- Summary of Transmissible Spongiform Encephalopathies Advisory Committee Meeting, June 1-2, 2000 - David Asher, M.D.

9:30 a.m. Open Committee Discussion

I. Plasma Pool Screening by Nucleic Acid Tests for Hepatitis A Virus

Α.]	Introduction and Background - Robin Biswas, M.D., Chief, Hepatitis Branch,Division of Emerging Transfusion Transmitted Diseases
В		Regulatory Options for HAV NAT - Sheryl
		Kochman, Chief, Devices Branch, DBA
C	7.	Review of History of Hepatitis A Transmitted
by		Transfusion, Mahmood Farshid, Ph.D.,
Regulatory		Scientist, Division of Hematology
D	Σ.	Hepatitis A Virus: Epidemiology/Clinical
		Implications/Prophylaxis - Stephen
Feinstone,		M.D., Chief, Laboratory of
Hepatitis Viruses,		Division of Viral
Products, OVRR		
E	Ξ.	HAV Transmission by Factor VIII Concentrates
-		Dr. Michael Chudy, Paul Erhlich Institute

10:30 a.m. BREAK

- 11:00 a.m. OPEN PUBLIC HEARING
- 11:30 a.m. Open Committee Discussion
 - F. FDA Perspective and Questions Robin Biswas, M.D., Medical Officer, DETTD
 - G. Committee Discussion and Recommendations
- 12:30 p.m. LUNCH
 - 1:30 p.m Open Committee Discussion

II. Development of Rapid HIV tests

- A. Background and Introduction Kimber Lee Poffenberger, Ph.D., Regulatory Scientist, DETTD
- B. Presentation 1LT Hassan S. Zahwa, M.S. Department of Defense
- C. Presentation Nancy A. Wade, M.D., M.P.H., Department of Health
- D. Presentation Robert S. Janssen, M.D., Director, Division of HIV/AIDS Prevention, Centers for Disease Control
- E. Presentation Bernard M. Branson, M.D., Centers for Disease Control and Prevention
- 2:30 p.m. OPEN PUBLIC HEARING
- 3:30 p.m. BREAK
- 4:00 p.m. Open Committee Discussion
 - F. Questions for the Committee Kimber Poffenberger, Ph.D.
 - G. Committee Discussion and Recommendations
- 5:00 p.m. Recess (until 9:00 a.m. Friday, June 16, 2000)

Friday, June 16, 2000

9:00 a.m. Committee Updates

- Update on Requirement for Syphilis Testing Martin Ruta, Ph.D., J.D.
- Regulation of HIV Drug Resistance Tests Martin Ruta, Ph.D., J.D.

NYS

- Risk of HCV to Sexual Partners Robin Biswas, M.D.
- Relative Sensitivity of HBsAg and HBV NAT Tests Robin Biswas, M.D.

9:30 a.m. Open Committee Discussion

III. Proposed FDA Guidance on Universal Leukoreduction: Current Thinking

- A. Introduction and Background Jong-Hoon Lee, M.D., Chief, Blood and Plasma Branch, DBA 10:30 a.m. **OPEN PUBLIC HEARING**
- 11:30 a.m. Open Committee Discussion
 - B. Committee Discussion and Recommendations
- 12:30 p.m. ADJOURNMENT